NCT06934538View on ClinicalTrials.gov

First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 17, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2029

Conditions
Unresectable Metastatic Colorectal CancerUnresectable Locally Advanced Colorectal Cancer
Interventions
BIOLOGICAL

STC-1010 + IS regimen + SOC therapy

STC-1010 administered with immunostimulants (IS) in low-dose (cyclophosphamide and GM-CSF) and standard of care (SOC) therapy (mFOLFOX6 with or without bevacizumab)

Trial Locations (9)

21287

NOT_YET_RECRUITING

Johns Hopkins, Baltimore

Unknown

NOT_YET_RECRUITING

Institut Jules Bordet, Brussels

RECRUITING

Institut Bergonié, Bordeaux

RECRUITING

Centre Georges François Leclerc (CGFL), Dijon

NOT_YET_RECRUITING

Centre Léon Bérard (CLB), Lyon

RECRUITING

Hospices Civils de Lyon (HCL), Lyon

RECRUITING

Institut du Cancer de Montpellier (ICM), Montpellier

NOT_YET_RECRUITING

Centre Hospitalier Universitaire de Poitiers (CHU), Poitiers

NOT_YET_RECRUITING

Institut Gustave Roussy (IGR), Villejuif

Sponsors

Lead Sponsor

Brenus Pharma
All Listed Sponsors
lead

Brenus Pharma

INDUSTRY

NCT06934538 - First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter